{"id":"https://openalex.org/W2904889682","doi":"https://doi.org/10.1182/blood-2018-99-115294","title":"Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States","display_name":"Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2904889682","doi":"https://doi.org/10.1182/blood-2018-99-115294","mag":"2904889682"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-115294","doi":"https://doi.org/10.1182/blood-2018-99-115294","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-115294","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087187822","display_name":"Jingbo Yu","orcid":"https://orcid.org/0000-0001-9819-0735","observed_orcids":["https://orcid.org/0000-0001-9819-0735"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jingbo Yu","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006893148","display_name":"Jonathan Karl Kish","orcid":"https://orcid.org/0000-0002-2824-8468","observed_orcids":["https://orcid.org/0000-0002-2824-8468"]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jonathan K. Kish","raw_affiliation_strings":["Cardinal Health, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health, Dallas, TX","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091492816","display_name":"Dilan Chamikara Paranagama","orcid":"https://orcid.org/0000-0001-6162-1992","observed_orcids":["https://orcid.org/0000-0001-6162-1992"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dilan Chamikara Paranagama","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033245617","display_name":"Jill Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jill Kaufman","raw_affiliation_strings":["Cardinal Health, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health, Dallas, TX","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110857698","display_name":"Jessica Chung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jessica Chung","raw_affiliation_strings":["Affiliation Name, Dallas, TX","Cardinal Health, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affiliation Name, Dallas, TX","institution_ids":[]},{"raw_affiliation_string":"Cardinal Health, Dallas, TX","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042176968","display_name":"Michael Richard Grunwald","orcid":"https://orcid.org/0000-0001-5407-9875","observed_orcids":["https://orcid.org/0000-0001-5407-9875"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Grunwald","raw_affiliation_strings":["Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075641618","display_name":"Philomena M. Colucci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philomena Colucci","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4390039360","display_name":"Mays Cancer Center at UT Health San Antonio","ror":"https://ror.org/04aysmc18","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165951966","https://openalex.org/I4390039360","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX","institution_ids":["https://openalex.org/I4390039360"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5006893148","https://openalex.org/A5033245617","https://openalex.org/A5091492816","https://openalex.org/A5110857698"],"corresponding_institution_ids":["https://openalex.org/I4210150323","https://openalex.org/I924451375"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"1765","last_page":"1765"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.984000027179718},{"id":"https://openalex.org/keywords/risk-stratification","display_name":"risk stratification","score":0.9409999847412109},{"id":"https://openalex.org/keywords/international-prognostic-scoring-system","display_name":"International Prognostic Scoring System","score":0.9599999785423279},{"id":"https://openalex.org/keywords/community-oncology-practice","display_name":"community oncology practice","score":0.6880000233650208},{"id":"https://openalex.org/keywords/treatment-initiation","display_name":"treatment initiation","score":0.3700000047683716},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9010000228881836},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.8989999890327454},{"id":"https://openalex.org/keywords/interferon","display_name":"interferon","score":0.7900000214576721},{"id":"https://openalex.org/keywords/post-polycythemia-vera-myelofibrosis","display_name":"post-polycythemia vera myelofibrosis","score":0.8330000042915344},{"id":"https://openalex.org/keywords/post-essential-thrombocythemia-myelofibrosis","display_name":"post-essential thrombocythemia myelofibrosis","score":0.9890000224113464},{"id":"https://openalex.org/keywords/jak2-mutation","display_name":"JAK2 mutation","score":0.6430000066757202},{"id":"https://openalex.org/keywords/nccn-guidelines-adherence","display_name":"NCCN guidelines adherence","score":0.5690000057220459},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.34299999475479126},{"id":"https://openalex.org/keywords/open-networks","display_name":"open networks","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8944240808486938},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8389587998390198},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.7627999186515808},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6251518726348877},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.5459129810333252},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.47228699922561646},{"id":"https://openalex.org/C2780829020","wikidata":"https://www.wikidata.org/wiki/Q408163","display_name":"Anagrelide","level":4,"score":0.4552828073501587},{"id":"https://openalex.org/C3020404979","wikidata":"https://www.wikidata.org/wiki/Q1058438","display_name":"Risk stratification","level":2,"score":0.4160107672214508},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.41167575120925903},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35360997915267944},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.27278822660446167},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.25970226526260376},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.17763885855674744},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.1554916501045227}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-115294","doi":"https://doi.org/10.1182/blood-2018-99-115294","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-115294","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3023532130","https://openalex.org/W4416584894","https://openalex.org/W7132127780","https://openalex.org/W4393993176","https://openalex.org/W4414853737","https://openalex.org/W7116304212","https://openalex.org/W2769174640","https://openalex.org/W2149055075","https://openalex.org/W2883135363","https://openalex.org/W2125783361"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"Myelofibrosis":[2],"(MF)":[3],"is":[4,91],"a":[5,210,352,437,562],"myeloproliferative":[6],"neoplasm":[7],"characterized":[8],"by":[9,101,219,410],"marrow":[10],"fibrosis,":[11],"extramedullary":[12],"hematopoiesis,":[13],"and":[14,22,69,104,144,146,176,178,190,256,269,301,308,316,326,375,398,504,514,521],"leukoerythroblastosis.":[15],"Clinical":[16,47],"manifestations":[17],"include":[18],"severe":[19],"anemia,":[20],"splenomegaly,":[21],"symptoms.":[23],"Median":[24,336],"survival":[25],"in":[26,75,82,127,313,355,369],"patients":[27,95,132,279,319,348,404,466,488,539,556,580],"with":[28,134,159,166,280,557],"primary":[29,135,304],"MF":[30,141,281,558],"ranges":[31],"from":[32,282,338,440,495],"2":[33],"to":[34,92,215,497,544,599,614],"11":[35],"years,":[36,297],"depending":[37],"on":[38,111,168,427,623,636,651,685,699,714,726,741,754,766,780,792],"risk":[39,58,97,108,179,195,212,259,265,353,367,389,409,423,431,438,449,455,541,563,568,592,608],"categorization.":[40],"The":[41,86,254,531],"National":[42],"Comprehensive":[43],"Cancer":[44,815],"Network":[45],"(NCCN)":[46],"Practice":[48],"Guidelines":[49],"recommend":[50],"the":[51,65,70,76,83,105,112,128,204,207,216,220,263,386,428,454,492,505,615],"International":[52],"Prognostic":[53],"Scoring":[54],"System":[55],"(IPSS)":[56],"for":[57,149,199,366,458,528],"stratification":[59,109],"at":[60,99,123,150,183,230,292,320,359,565,594],"diagnosis;":[61],"other":[62],"systems":[63],"including":[64],"Dynamic":[66],"IPSS":[67,194,376,430],"(DIPSS)":[68],"DIPSS-Plus":[71],"are":[72,80,96],"also":[73,223],"cited":[74,526],"Guidelines.":[77,85],"Treatment":[78],"recommendations":[79],"risk-adapted":[81],"NCCN":[84],"objective":[87],"of":[88,114,206,252,258,262,277,318,322,347,371,465,484,555,579,586,617,627,640,655,689,703,718,730,745,758,770,784,796],"this":[89],"study":[90],"describe":[93],"how":[94],"stratified":[98],"diagnosis":[100,184,231,293,339,496,595,604],"community":[102,124,284],"hematologists/oncologists":[103],"impact":[106],"that":[107],"has":[110],"initiation":[113,499,533],"MF-directed":[115,235,476,490],"treatments.":[116],"Methods":[117],"Medical":[118],"chart":[119],"reviews":[120],"were":[121,154,157,226,272,287,299,311,328,333,378,406,511,524,573,590,596],"conducted":[122],"hematology/oncology":[125,285],"practices":[126,286],"OPEN":[129],"network.":[130],"Adult":[131],"diagnosed":[133],"MF,":[136,138],"post-PV":[137],"or":[139,187,240,243,421,479,629,642,657,691,705,720,732,747,760,772,786,798],"post-ET":[140],"between":[142],"1/2012":[143],"12/2016":[145],"receiving":[147,489],"care":[148],"least":[151],"6":[152],"months":[153,342,483,502,585],"included.":[155,288],"Data":[156],"collected":[158],"an":[160,447,624,637,652,686,700,715,727,742,755,767,781,793],"electronic":[161],"case":[162],"report":[163],"form":[164],"(eCRF)":[165],"questions":[167],"clinical":[169,241],"characteristics":[170],"(symptoms,":[171],"Hgb,":[172],"WBC,":[173],"blast":[174],"%,":[175],"PLT)":[177],"assessment":[180],"method":[181],"used":[182,218,365],"(IPSS,":[185],"DIPSS,":[186],"DIPSS-Plus),":[188],"treatments,":[189],"outcomes.":[191],"A":[192,275,361],"data-derived":[193,211,267,388,429],"score":[196],"was":[197,222,294,340,364,456,500,535,569],"calculated":[198],"each":[200],"patient.":[201],"To":[202],"assess":[203],"accuracy":[205,261],"assigned":[208,408],"risk,":[209,268],"score,":[213],"corresponding":[214,387],"system":[217,363],"provider,":[221],"calculated.":[224],"Patients":[225,588],"classified":[227,542,547,593],"as":[228],"treated":[229],"if":[232],"they":[233],"received":[234,436,446,475,581],"therapy":[236],"(hydroxyurea,":[237],"interferon,":[238],"ruxolitinib,":[239],"trial)":[242],"allogeneic":[244],"hematopoietic":[245],"cell":[246],"transplant":[247],"(HCT)":[248],"within":[249,481,583],"120":[250],"days":[251],"diagnosis.":[253,360,485,566,587],"methods":[255],"rates":[257],"stratification,":[260],"provider-assigned":[264],"versus":[266,549,605],"treatment":[270,478,498,529,532,582,601],"administered":[271],"reported.":[273],"Results":[274],"total":[276],"338":[278,384],"28":[283],"Mean":[289],"(SD)":[290],"age":[291],"65.3":[295],"(11.8)":[296],"51.8%":[298],"male,":[300],"68.3%":[302],"had":[303,416],"MF.":[305],"JAK2,":[306],"MPL,":[307],"CALR":[309],"mutations":[310],"tested":[312],"86.1%,":[314],"70.1%,":[315],"60.9%":[317],"diagnosis,":[321],"these,":[323],"71.1%,":[324],"23.2%,":[325],"14.6%":[327],"positive,":[329],"respectively;":[330],"18.4%":[331],"(38/206)":[332],"triple":[334],"negative.":[335],"follow-up":[337],"27.5":[341],"(IQR,":[343],"18.5-42.6).":[344],"Approximately":[345],"32%":[346],"did":[349,559],"not":[350,407,560],"have":[351],"classification":[354,439,564],"their":[356,411,441],"medical":[357],"records":[358],"scoring":[362],"assignment":[368],"45.3%":[370],"patients;":[372],"DIPSS":[373],"(23.0%)":[374],"(21.3%)":[377],"most":[379,415,459,506],"commonly":[380],"used.":[381],"Of":[382,433],"all":[383,487],"patients,":[385,453],"classifications":[390],"were:":[391],"5.6%":[392],"low,":[393],"20.1%":[394],"int-1,":[395,470],"18.3%":[396],"int-2,":[397,472],"55.9%":[399,469],"high":[400,422],"risk.":[401,618],"Among":[402,486],"those":[403,434,538,545,606],"who":[405,435,589],"treating":[412,442],"physicians":[413],"(n=108),":[414],"int-1":[417],"(28.7%),":[418],"int-2":[419],"(17.6%),":[420],"(43.5%)":[424],"disease":[425],"based":[426],"classification.":[432],"physician,":[443],"47.4%":[444],"(n=109)":[445],"inaccurate":[448],"classification;":[450],"among":[451,537],"these":[452],"under-estimated":[457],"(82.6%)":[460],"(Table":[461],"1).":[462],"Overall,":[463],"55.8%":[464],"(63.2%":[467],"low-risk,":[468],"52.5%":[471],"56.1%":[473],"high-risk)":[474],"pharmacological":[477,509],"HCT":[480],"4":[482],"treatment,":[491],"mean":[493],"time":[494],"5.3":[501],"(SD=1.8),":[503],"common":[507],"first":[508],"treatments":[510],"ruxolitinib":[512],"(49.8%)":[513],"hydroxyurea":[515],"(46.7%).":[516],"Splenomegaly":[517],"(81.3%),":[518],"symptoms":[519],"(72.6%),":[520],"anemia":[522],"(65.6%)":[523],"top":[525],"indications":[527],"initiation.":[530],"rate":[534],"higher":[536],"correctly":[540,591],"compared":[543],"incorrectly":[546,574,607],"(64.2%":[548],"49.5%,":[550],"p=0.032).":[551],"Conclusions":[552],"Nearly":[553],"one-third":[554],"receive":[561],"When":[567],"assigned,":[570],"almost":[571],"half":[572,578],"classified.":[575],"Just":[576],"over":[577],"four":[584],"more":[597],"likely":[598],"start":[600],"promptly":[602],"upon":[603],"classified,":[609],"which":[610],"may":[611],"be":[612],"attributable":[613],"under-estimation":[616],"Disclosures":[619],"Verstovsek:":[620],"Celgene:":[621,723,839],"Membership":[622,635,650,684,698,713,725,740,753,765,779,791],"entity's":[625,638,653,687,701,716,728,743,756,768,782,794],"Board":[626,639,654,688,702,717,729,744,757,769,783,795],"Directors":[628,641,656,690,704,719,731,746,759,771,785,797],"advisory":[630,643,658,692,706,721,733,748,761,773,787,799],"committees;":[631,707,722,734,749,762,788,800],"Incyte:":[632],"Consultancy;":[633,843],"Novartis:":[634,842],"committees,":[644,693,774],"Research":[645,679,694,709,775,803,820,823,826,830,834,837,840,845],"Funding,":[646],"Speakers":[647],"Bureau;":[648],"Italfarmaco:":[649],"committees.":[659],"Yu:Incyte":[660],"Corporation:":[661,682,829],"Employment,":[662,669,806],"Equity":[663,670,736,807],"Ownership.":[664,671,808],"Kish:Cardinal":[665],"Health:":[666,673,676,751],"Employment.":[667,674,677],"Paranagama:Incyte:":[668],"Kaufman:Cardinal":[672],"Chung:Cardinal":[675],"Grunwald:Genentech:":[678],"Funding;":[680,695,710,776,821,824,827,831,835,838,841],"Incyte":[681,828],"Consultancy,":[683,697,712,724,739,752,764,778,790],"Agios:":[696],"Janssen:":[708],"Alexion:":[711],"Medtronic:":[735],"Ownership;":[737],"Pfizer:":[738,844],"Cardinal":[750],"Amgen:":[763],"Merck:":[777],"Ariad:":[789],"Forma":[801],"Therapeutics:":[802],"Funding.":[804,846],"Colucci:Incyte:":[805],"Mesa:UT":[809],"Health":[810],"San":[811],"Antonio":[812],"-":[813],"Mays":[814],"Center:":[816],"Employment;":[817],"NS":[818],"Pharma:":[819],"Promedior:":[822],"Gilead:":[825],"CTI":[832],"Biopharma:":[833],"Genentech:":[836]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-12-22T00:00:00"}